Surrey Heartlands

Joint Formulary & PAD

Roflumilast - Chronic Obstructive Pulmonary Disease (COPD)

You are here : Home > Formulary Search > Roflumilast - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NICE
Restrictions / Comments :
Important
Restricted to initiation by respiratory specialists in line with NICE TA461. https://www.gov.uk/drug-safety-update/roflumilast-daxas-risk-of-suicidal-behaviour

Documentation

Shared Care
Roflumilast - Prescribing Information Sheet - Feb 2018
NICE Technology Appraisal
NICE TA461 - Roflumilast for treating COPD
Evidence Review
Roflumilast for the treatment of COPD - NICE briefing paper - October 2017

PAD Profile

ChemicalSubstance :
Roflumilast
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
Keywords :
Chronic Obstructive Pulmonary Disease
Brand Names Include :
Daxas
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Chronic Obstructive Pulmonary Disease (COPD)
Supporting Documents :
3

Other Indications

Below are listed other indications that Roflumilast is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

04 Oct 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends roflumilast as a treatment option for COPD in line with NICE TA461

Roflumilast will be considered BLUE on the traffic light system with initiation by respiratory consultants.

There should be a minimum of 3 months prescribing in secondary care prior to transfer of care to primary care prescribers.